March 6 (Reuters) - AbbVie Inc (NYSE:ABBV) ABBV.N :
* ABBVIE RECEIVES POSITIVE RECOMMENDATION FROM THEPAN-CANADIANONCOLOGY DRUG REVIEW FOR VENCLEXTA™ - AN ORAL THERAPY FOR THETREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
* ABBVIE CANADA - PCODR CONDITIONALLY RECOMMENDSREIMBURSEMENT OFVENCLEXTA FOR CLL PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIORTHERAPY & FAILED A BCRI